Clinical Trial

Non-invasive Evaluation of the Predictive Value of CEUS and SWE in ACLF, Renal Failure and Hepatorenal Syndrome

Study acronym: NECTAR
Recruiting
View on ClinicalTrials.gov →
Summary
Evaluation of non-invasive prognostic parameters in patients developing ACLF and renal failure in patients receiving and not receiving transjugular intrahepatic portosystemic shunt (TIPS). Patients are cared according to the local standardized follow up program. Clinical and laboratory data from standard patient care are evaluated for potential prognostic value.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-06-22; most recent amendment 2022-05-17.
Status change: Not Yet Recruiting → Recruiting 2021-04-27
Trial Details
NCT Number NCT04446858
Lead Sponsor University Hospital, Bonn
Conditions Kidney Failure, Acute
Enrollment 1,000 participants
Start Date 2021-01-01
Primary Completion 2030-07-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2022-05-18